Break Free From Depression
Discover innovative solutions for Treatment-Resistant Depression at SIA-LLC in Maryville, IL.
Treatment-resistant depression (TRD)
is when a person’s depression does not adequately respond to multiple standard treatments. These standard treatments typically include antidepressant medications and psychotherapy. About one-third of people with depression may experience treatment-resistant symptoms.
Approaches to treatment for treatment-resistant depression can vary depending on the severity of the condition and individual factors. Here are some common approaches:
1. Medication adjustments: In cases of treatment-resistant depression, doctors may explore different medications or combinations of medications. They may adjust the dosage, change the medication class, or add augmentation agents to enhance the antidepressant effects.
2. Psychotherapy modifications: Different forms of psychotherapy, such as cognitive-behavioral therapy (CBT) or interpersonal therapy (IPT), may be tried. Therapists may also modify the therapeutic approach to address specific symptoms or underlying issues.
3. Electroconvulsive therapy (ECT): ECT involves administering electrical currents to the brain under general anesthesia. It is when other treatments have failed, and it has shown to be highly effective in treating severe depression. ECT may cause side effects, such as short-term memory loss.
4. Transcranial magnetic stimulation (TMS): TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is when other treatments have not been successful. TMS is usually well-tolerated and has fewer side effects compared to ECT.
5. Esketamine: Esketamine is a nasal spray medication that targets the NMDA receptors in the brain. It has been approved for the treatment of treatment-resistant depression when used in combination with an oral antidepressant. Esketamine can have rapid antidepressant effects, but it also has potential side effects, such as dissociation and increases in blood pressure.
6. Vagus nerve stimulation (VNS): VNS involves the implantation of a device that stimulates the vagus nerve, which is connected to various brain regions involved in mood regulation. The device sends electrical signals to the brain, and it is typically used in cases of severe treatment-resistant depression. VNS may cause side effects such as voice changes or hoarseness.
It is important to note that the specific treatment approach for treatment-resistant depression should be determined by a qualified healthcare professional based on an individual’s unique circumstances and medical history. These treatment options may have varying success rates and potential side effects, so a thorough evaluation is crucial to determine the best course of action.
Transcranial magnetic stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that utilizes magnetic fields to stimulate nerve cells in the brain, aiming to alleviate symptoms of depression. This treatment is particularly beneficial for individuals whose depression has not responded to traditional methods such as medication or psychotherapy.
TMS involves delivering repetitive magnetic pulses, hence the term repetitive TMS (rTMS). During the procedure, an electromagnetic coil is placed against the scalp near the forehead. The magnetic pulses generated by the coil pass through the skull and induce electrical currents in the targeted regions of the brain involved in mood regulation. These pulses are designed to activate nerve cells and improve communication within the brain circuits that influence depression.
The treatment sessions are typically conducted five times a week for several weeks, with each session lasting about 30 minutes. Patients remain awake and alert during the procedure, and the side effects are usually mild, including scalp discomfort or headaches.
TMS offers a promising alternative for those struggling with treatment-resistant depression, providing hope and potential relief when other options have failed.
SPRAVATO
Spravato is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.
SPRAVATO® is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for the treatment of:
• Treatment-resistant depression (TRD) in adults.
• Depressive symptoms in adults with major depressive disorder (MDD) with
acute suicidal ideation or behavior.
